The	O
association	O
between	O
HIV	B:C0019693
,	O
antiretroviral	B:C1963724
therapy	I:C1963724
,	O
and	O
gestational	B:C0085207
diabetes	I:C0085207
mellitus	I:C0085207
.	O

The	O
widespread	B:C0205391
,	O
chronic	O
use	O
of	O
antiretroviral	B:C1963724
therapy	I:C1963724
raises	O
questions	B:C1522634
concerning	O
the	O
metabolic	O
consequences	O
of	O
HIV	B:C0019693
infection	I:C0019693
and	O
treatment	B:C0087111
.	O

Antiretroviral	B:C1963724
therapy	I:C1963724
,	O
and	O
specifically	O
protease	B:C0033607
inhibitors	I:C0033607
,	O
has	O
been	O
associated	O
with	O
hyperglycemia	B:C0020456
.	O

As	O
pregnant	B:C0033011
women	I:C0033011
are	O
vulnerable	O
to	O
development	O
of	O
hyperglycemia	B:C0020456
,	O
the	O
objective	B:C0018017
of	O
this	O
study	B:C2603343
was	O
to	O
explore	O
existing	O
literature	B:C0023866
on	O
the	O
relationship	O
between	O
HIV	B:C0019693
infection	I:C0019693
,	O
HIV	B:C0019693
treatment	B:C0087111
,	O
and	O
gestational	B:C0085207
diabetes	I:C0085207
mellitus	I:C0085207
(	O
gestational	B:C0085207
diabetes	I:C0085207
mellitus	I:C0085207
)	O
.	O

A	O
systematic	O
search	O
was	O
conducted	O
in	O
six	O
databases	B:C0242356
for	O
articles	B:C1706852
providing	O
data	O
on	O
HIV	B:C0019699
-	I:C0019699
positivity	I:C0019699
,	O
protease	B:C0033607
inhibitor	I:C0033607
exposure	O
,	O
and	O
gestational	B:C0085207
diabetes	I:C0085207
mellitus	I:C0085207
or	O
glucose	B:C0342307
intolerance	I:C0342307
development	I:C0342307
in	I:C0342307
pregnancy	I:C0342307
.	O

The	O
quality	O
of	O
articles	B:C1706852
was	O
evaluated	B:C0220825
using	O
an	O
adapted	O
Cochrane	B:C0282574
Collaboration	I:C0282574
bias	I:C0282574
assessment	I:C0282574
tool	I:C0282574
.	O

Risk	O
ratios	O
were	O
generated	O
from	O
pooled	O
data	O
using	O
meta-	B:C0920317
analysis	I:C0920317
by	O
the	O
Mantel	B:C1710191
-	I:C1710191
Haenszel	I:C1710191
method	I:C1710191
.	O

Of	O
891	O
references	B:C1514811
screened	O
,	O
six	O
studies	B:C2603343
on	O
the	O
role	O
of	O
HIV	B:C0019699
-	I:C0019699
positivity	I:C0019699
,	O
10	O
on	O
protease	B:C0033607
inhibitor	I:C0033607
use	O
,	O
and	O
two	O
on	O
both	O
were	O
included	O
.	O

Meta	B:C0920317
-	I:C0920317
analysis	I:C0920317
showed	O
no	B:C1273937
significant	I:C1273937
relationship	O
between	O
HIV	B:C0019693
infection	I:C0019693
and	O
the	O
development	O
of	O
gestational	B:C0085207
diabetes	I:C0085207
mellitus	I:C0085207
[	O
risk	O
ratio	O
0.80	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
0.47	O
-	O
1.37	O
,	O
I	O
=	O
0	O
%	O
]	O
.	O

Meta	B:C0920317
-analysis	I:C0920317
of	O
protease	B:C0033607
inhibitor	I:C0033607
exposure	O
showed	O
increased	O
gestational	B:C0085207
diabetes	I:C0085207
mellitus	I:C0085207
in	O
studies	B:C2603343
using	O
first	B:C0033607
-	I:C0033607
generation	I:C0033607
protease	I:C0033607
inhibitors	I:C0033607
(	O
risk	O
ratio	O
2.29	O
,	O
95	O
%	O
CI	O
:	O
1.46	O
-3.58	O
)	O
and	O
studies	B:C2603343
using	O
the	O
strictest	O
diagnosis	B:C0679228
criteria	I:C0679228
,	O
the	O
National	B:C0679228
Diabetes	I:C0679228
Data	I:C0679228
Group	I:C0679228
criteria	I:C0679228
for	O
3	O
-h	O
oral	B:C0029161
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
(	O
risk	O
ratio	O
3.81	O
,	O
95	O
%	O
CI	O
:	O
2.18	O
-	O
6.67	O
)	O
.	O

Meta	B:C0920317
-analysis	I:C0920317
showed	O
no	B:C1273937
significant	I:C1273937
association	O
between	O
HIV	B:C0019699
-	I:C0019699
positivity	I:C0019699
and	O
gestational	B:C0085207
diabetes	I:C0085207
mellitus	I:C0085207
.	O

Significance	O
of	O
protease	B:C0033607
inhibitor	I:C0033607
use	O
was	O
limited	O
to	O
studies	B:C2603343
using	O
the	O
strictest	O
diagnostic	B:C0679228
criteria	I:C0679228
for	O
gestational	B:C0085207
diabetes	I:C0085207
mellitus	I:C0085207
.	O

Results	O
are	O
limited	O
by	O
high	B:C0332167
risk	I:C0332167
of	I:C0332167
bias	O
.	O

Well	O
designed	O
prospective	B:C0033522
studies	I:C0033522
are	O
needed	O
to	O
further	O
clarify	O
this	O
relationship	O
and	O
its	O
consequences	O
for	O
clinical	O
practice	O
.	O

